Sector ratings MedinCell S.A.

Equities

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-01-22 am EST			After hours 03:42:30 pm
28.74 ^EUR	+3.60%		28.71	-0.10%

Dec. 10	Medincell Narrows Operating Loss in First Half
Dec. 10	MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment	MT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
MEDINCELL S.A.	1.07B	-	-	-		-
ELI LILLY AND COMPANY	966B		A
JOHNSON & JOHNSON	525B		BBB
ABBVIE INC.	382B		AA
ROCHE HOLDING AG	371B		AA
ASTRAZENECA PLC	278B		A
NOVARTIS AG	276B		AAA
MERCK & CO., INC.	276B		A
NOVO NORDISK A/S	260B		A
AMGEN INC.	185B		A
GILEAD SCIENCES, INC.	160B		AAA
PFIZER INC.	147B		BBB
VERTEX PHARMACEUTICALS INCORPORATED	117B		AA
BRISTOL-MYERS SQUIBB COMPANY	111B		A
SANOFI	111B		A
GSK PLC	96.35B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	86.54B		AA
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	57.39B		AA
TAKEDA PHARMACEUTICAL COMPANY LIMITED	49.69B		AA
Average	226B		AA
Weighted average by Cap.			AA